Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen
1138245-13-2CCC1=C[C@@H]2[C@H](C1)C[C@]2(CN)CC(=O)OFTBQORVNHOIASH-CKYFFXLPSA-NSicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
N - Nervous system;N02 - Analgesics;N02B - Other analgesics and antipyretics;N02BF - Gabapentinoids;N02BF03 - Mirogabalin
QN - Nervous system;QN02 - Analgesics;QN02B - Other analgesics and antipyretics;QN02BF - Gabapentinoids;QN02BF03 - Mirogabalin
BeschreibungMirogabalin is a calcium channel blocker with analgesic effects. It binds to the α2δ-1 and α2δ-2 subunits of voltage-dependent Ca2+ channels. Mirogabalin has potent and sustained analgesic effects (ED50 = 2.5 mg/kg) in rats with diabetes induced by streptozotocin (STZ; ). Mirogabalin does not inhibit activities associated with CNS adverse effects of analgesics, such as rotarod performance (ID50 = 9.4 mg/kg) or locomotor activity (ID50 = 43.9 mg/kg), at its effective dose. Formulations containing mirogabalin are in clinical trials for diabetic peripheral neuropathic pain.
VerwendenMirogabalin is a two alpha2delta ligand which is investigated for the treatment of peripheral neuropathic pain, postherpetic neuralgia and fibromyalgia, showing promising results in patients with diabetic peripheral neuropathy.
Wird geladen…
1138245-13-2DTXSID001032301CHEMBL3545125